44results about How to "Overcoming multidrug resistance" patented technology

The invention provides a polydopamine and polyethylene glycol vitamin E succinate-modified mesoporous silica nanoparticle as well as a preparation method and application thereof. Specifically, the preparation method of the polydopamine and polyethylene glycol vitamin E succinate-modified mesoporous silicon dioxide nanoparticle comprises the following steps: 1) dissolving mesoporous silicon dioxide and a drug into a solvent, reacting to be complete and separating to obtain a drug-loaded mesoporous silica initial nanoparticle; 2) adding the initial nanoparticle into a solution, adding dopamine hydrochloride, reacting to be complete and separating to obtain a drug-loaded polybutadiene-wrapped mesoporous silica nanoparticle; 3) adding the polybutadiene-wrapped mesoporous silica nanoparticle into a weak base aqueous solution, adding polyethylene glycol 1000 vitamin E succinate, reacting to be complete and separating to obtain a tumor targeting mesoporous silica nanoparticle. The nanoparticle provided by the invention is simple in preparation method, free from pollution and good in biocompatibility and biodegradability, and has a treatment effect on a lung cancer.

The invention relates to a preparation method of multilevel slow-release drug-loaded short nano-fibers. According to the method, layered double hydroxides (LDH) loaded doxorubicin (DOX) serving as ananti-cancer drug and alpha-tocopherol succinate (alpha-TOS) serving as a P-gp inhibitor are mixed into polylactic acid-glycolic acid copolymer (PLGA) spinning solution, and electrostatic spinning andhomogeneous treatment are implemented to obtain the fibers. The multilevel slow-release double medicine carrying short nano-fibers are built by the aid of organic and inorganic double carriers, multilevel release of the anti-cancer drug and the P-gp inhibitor in materials can be achieved in tumor micro-acidic environments, multi-drug resistance of cancer cells is overcome, the double-carrier nano-fibers lengthen release paths of the drugs, slow release of the anti-cancer drug is achieved, and a novel method is provided for long-term and effective treatment of drug-resistant tumors.

The invention belongs to the field of medicine, and relates to the application of deuterium-depleted water (DDW) in reversing multidrug resistance of tumors and antitumor drug sensitizers. Deuterium-depleted water is a natural product, which has the function of reversing the multidrug resistance of tumor cells, and can be used as a reversal agent for tumor multidrug resistance; at the same time, deuterium-depleted water has the effect of increasing the sensitivity of tumor multidrug-resistant cells to anti-tumor drugs. It can be used as a drug sensitizer for anti-tumor cells. The invention provides deuterium-depleted water as an adjuvant therapeutic agent for tumor treatment, which can be used alone or in combination with one or more antitumor drugs. The present invention also relates to using deuterium-depleted water alone or in combination with one or more anti-tumor drugs in daily tumor treatment, and the deuterium-depleted water contains 0.01-100 ppm of deuterium.

The invention relates to the technical field of medicine, and specifically relates to nitrogen-substituted dihydroartemisinin phenyl ether, optical isomers thereof and a preparation method thereof; pharmaceutical compositions with the derivatives as active components; and applications thereof in preparing medicines used for treating and / or preventing various cancers. The compound or pharmaceutically acceptable salts thereof have a structure as the following. The variables are as described in the claims and in the specifications. According to the invention, a pair of epimers with dihydroartemisinin C-10 site of R or S configuration can be prepared at a same time and with an equal amount, and separation can be realized. The prepared compounds have a significant effect in inhibiting cancer cell growth, and a selective killing effect against drug-resistant cells. The compounds have a potential of overcoming multidrug resistance.

The invention discloses a natural small molecule co-assembled nano-drug delivery system as well as a preparation method and application thereof. The natural small molecule co-assembled nano-drug delivery system is a nano-particle formed by co-assembling two or more than two of oleanolic acid, ursolic acid, glycyrrhetinic acid, betulinic acid, betulin, liquidambaric acid, lupeol, paclitaxel, rheinic acid and catechinic. The original self-assembly morphology of a compound can be changed, nanoparticles with different morphologies and sizes are prepared, and the problem that the morphology of compounds is not suitable for intravenous injection is solved. The nano-drug delivery system disclosed by the invention has one or more pharmacological activities, the compounds forming the nano-drug delivery system play a synergistic anti-tumor role through different mechanisms, and the system has health-care functions and can be used for improving the oxidation resistance of an organism.

A composition of an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water nanoemulsion (NE) drug delivery system. A method of treating cancer by administering an effective amount of a pharmaceutical composition including a PUFA-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system to a subject in need of treatment, and treating cancer. A method of overcoming multidrug resistance by exposing a multidrug resistant cell to an effective amount of a pharmaceutical composition including an omega-3 polyunsaturated fatty acid (PUFA)-taxoid conjugate encapsulated in an oil-in-water NE drug delivery system, and inducing the death of the multidrug resistant cell. A method of eliminating a cancer stem cell. Methods of reducing stemness of a cancer stem cell, retaining drug in the body, and providing a slower release profile.

The invention provides an anticancer intermediate based on PKI-587 and a polyethylene glycol coupled anticancer drug, and preparation methods and application thereof, belonging to the field of treatment of cancers. The anticancer intermediate has a general structural formula as described in the specification, and at least one AC in the general structural formula is the anticancer drug PKI-587. Thepolyethylene glycol coupled anticancer drug has a general structural formula as described in the specification. The above two drugs can realize combined medication of the targeting anticancer drug PKI-587 and a plurality of other anticancer drugs, so toxic response caused by mutual influence and pharmacokinetics of a plurality of other anticancer drugs can be prevented during individual administration of the anticancer drugs, multidrug resistance of cancers is overcome, and synergistic effect is exerted; and the two drugs can be used for preparing anticancer drugs with targeting effect and have critical clinical value and wide market prospects.

The invention discloses composite micelle carrying an anti-tumor medicine and a preparation method thereof. The composite micelle is prepared from the following raw materials: pluronic, an amphiphilic block copolymer, an anti-tumor medicine, an organic solvent and water, wherein the mass ratio of the pluronic to the amphiphilic block copolymer is 1-1000:10; the mass ratio of the total mass of thepluronic and the amphiphilic block copolymer to the anti-tumor medicine is 2-100:1. The invention combines the advantages of the pluronic and the amphiphilic block copolymer, and the prepared composite micelle has uniform particle diameter and can overcome a multidrug resistance action. Fluorescent HPLC proves that the composite micelle can obviously increase the intracellular accumulation of themedicine and can be applied to the field of the reversion of the multidrug resistance of tumors. The invention has simple preparation method and very good application prospect.

The invention discloses a drug injectant for curing dairy cow mastitis. The drug injectant comprises a specific anti-DP-BM-IgY egg yolk antibody and an extracting solution of a traditional Chinese medicine composition, and relates to an injectant for breasts. The invention further provides a preparation method and application of the drug injectant. The rug injectant provided by the invention has the beneficial effects as followings: the specific anti-DP-BM-IgY egg yolk antibody can be used for killing main pathogenic bacteria of dairy cow mastitis directionally, plays an obvious curative role on various of mastititides, and has the characteristics of stable quality, strong specificity, zero residue and no resistance to drugs; the traditional Chinese medicine composition also has the efficacies of dissipating blood stasis and relieving pain, repelling poison and dispelling pus, cooling blood and relieving swelling, resisting bacterium and eliminating inflammation, and enhancing immunity; the drug injectant for breasts, obtained through combination, can be directly applied into breasts locally, the targeting effect is better, therefore, bioavailability and drug therapeutic effect are improved, the treatment for diseases is more effective and accurate, the whole body toxic and side effects caused by drugs can be lowered, adverse drug reactions are reduced, the use is convenient, the compliance is good, and the safety in use is enhanced.

The present invention relates to a preparation method of multi-level sustained-release drug-loaded nano-short fibers, comprising layered double hydroxide (LDH) loaded with anticancer drug doxorubicin (DOX) and P-gp inhibitor α-growth Phenolsuccinate (α-TOS) was mixed together in poly(lactic-co-glycolic acid) (PLGA) spinning solution for electrospinning and homogenized. The present invention constructs double-loaded multi-level slow-release drug-loaded nano-short fibers with organic and inorganic dual carriers. The anticancer drugs and P-gp inhibitors in the material can be released in multiple levels in the slightly acidic environment of the tumor, and are used to overcome cancer. The multi-drug resistance of cells, the double-carrier nanofiber prolongs the drug release path, realizes the long-term sustained release of anticancer drugs, and provides a new method for the long-term effective treatment of drug-resistant tumors.

The invention discloses a mixed micelle freeze-dried preparation loaded with docetaxel. A preparation method of the mixed micelle freeze-dried preparation loaded with docetaxel comprises the following steps of: dissolving docetaxel, a Pluronic surfactant and a diblock copolymer into an organic solvent, rotationally evaporating the organic solvent out under reduced pressure under a water bath condition, and standing in vacuum to obtain a dry and transparent medicament film; heating the medicament film in a water bath, melting a solid framework, adding water of the same temperature for hydrating, and cooling to the room temperature to obtain a transparent docetaxel mixed micelle solution; and adding a freeze-drying protecting agent into the docetaxel mixed micelle solution, degerming with a microporous filtering film, and performing freeze drying to obtain a mixed micelle freeze-dried preparation of docetaxel, wherein the average particle diameter of the mixed micelle freeze-dried preparation is 17-25 nanometers. According to the mixed micelle freeze-dried preparation loaded with docetaxel disclosed by the invention, the solubility of docetaxel is increased greatly; and a prepared micelle has small particle diameter and high envelop rate, has the characteristics of passive targeting, long circulation and the like, and has a very good application prospect.

The invention belongs to the field of pharmaceutics and particularly relates to a method for preparing solid lipid nanoparticles of water-soluble anti-tumor medicine. The method comprises the steps of: dissolving stearic acid and lecithin in organic solvent, mixing, dropping anti-tumor medicine under the condition of water bath, stirring and slowly injecting polyanion sodium alginate so as to packing the medicine and the sodium alginate in nanoparticles, and acquiring the solid lipid nanoparticles by temperature changing, probe ultrasonic treatment and filter membrane treatment. In the invention, the adriamycin capsulated in the solid lipid nanoparticles is combined with the alginate so as to greatly increase the encapsulation rate, lower the absorption of surface medicine, and delay the release of the anti-tumor medicine for achieving the purpose of reducing the suddenly releasing of the medicine. Compared with the other method for increasing the encapsulation rate, the method provided by the invention is simple to operate, is low in preparing material demand and high in encapsulation rate, and can efficiently overcome multidrug resistance.

The invention discloses a traditional Chinese medicine capsule for treating breast cancer and a preparation method thereof. The capsule comprises a housing material and a filling material, wherein a mass ratio of the housing material and the filling material is 1-4:1. According to the parts by weight: the housing material comprises 11-30 parts of fibroin, 6-21 parts of sericin, 1-6 parts of gelatin, and 1-4 parts of hyaluronic acid; and the filling material comprises 11-21 parts of an astragalus membranaceus extract, 8-19 parts of a rhizoma atractylodis macrocephalae extract, 8-22 parts of a prunella vulgaris extract, 5-21 parts of a lonicera japonica extract, 3-18 parts of a liquorice extract, 3-16 parts of a dandelion extract, 2-11 parts of a pericarpium citri reticulatae extract, 3-11 parts of a malt extract, 1-5 parts of almond oil, and 1-3 parts of a vitamin A. The capsule is capable of assisting a western medicine therapy to treat the breast cancer, improving clinical symptoms ofa patient, reducing the chemoradiotherapy toxic and side effects, overcoming the multidrug resistance of cancer cells, regulating a body immunity mechanism, improving the effects of operations, radiotherapy and chemotherapy, improving the living quality of the patient, and prolonging the lifetime.

The invention provides ammonia borane / hollow mesoporous polydopamine / polyethylene glycol nanocomposite particles, the chemical formula of the nanocomposite particles is AB@HMPDA‑PEG, with solid silica as the core and mesoporous polydopamine as the shell , etched with hydrofluoric acid to obtain hollow mesoporous polydopamine HMPDA, PEG-modified on the surface of the shell, and then encapsulated ammonia borane AB small-molecule prodrug by hydrogen bond force. The invention also provides the preparation method and application of the nanocomposite particles. Compared with the prior art, the AB@HMPDA‑PEG nanocomposite particles of the present invention can target anticancer drugs and gaseous prodrugs to the cancer site, increase the long circulation time in the body while reducing the toxic side effects on normal tissues and cells , Overcome multidrug resistance to kill cancer cells more efficiently, further improve the therapeutic effect, and have great potential in promoting the combined application of gas therapy and cancer chemotherapy, and enhancing the efficacy of cancer treatment.

The invention belongs to the field of novel nanometer drugs, and discloses an esterase-responsive polycurcumin thiodipropionic acid copolymer prodrug nano-micelle, a preparation method and applications thereof, wherein the esterase-responsive polycurcumin thiodipropionic acid copolymer prodrug nano-micelle comprises, by mass, 28-93.6% of a carrier auxiliary material and 6.4-72% of a curcumin drug,the nano-micelle monomer is an amphiphilic block and comprises a hydrophilic segment and a hydrophobic segment, the hydrophilic block is methoxy polyethylene glycol with a molecular weight of 1500-6000, the hydrophobic chain segment is a curcumin poly prodrug short chain co-polymerized from thiodipropionic acid and an anticancer drug curcumin and having a molecular weight of 800-12000, and a weight ratio of the hydrophilic segment methoxypolyethylene glycol to the curcumin poly prodrug short chain is 0.1-20:1. According to the present invention, the novel nano-micelle monomer can be degradedand reduced under the action of the esterase in the cancer cells to obtain the anticancer drug curcumin bulk drug so as to achieve the precise controlled-release effect.

The invention relates to the technical field of medicine, and specifically relates to nitrogen-substituted dihydroartemisinin phenyl ether, optical isomers thereof and a preparation method thereof; pharmaceutical compositions with the derivatives as active components; and applications thereof in preparing medicines used for treating and / or preventing various cancers. The compound or pharmaceutically acceptable salts thereof have a structure as the following. The variables are as described in the claims and in the specifications. According to the invention, a pair of epimers with dihydroartemisinin C-10 site of R or S configuration can be prepared at a same time and with an equal amount, and separation can be realized. The prepared compounds have a significant effect in inhibiting cancer cell growth, and a selective killing effect against drug-resistant cells. The compounds have a potential of overcoming multidrug resistance.

The invention discloses a gold medicinal nano-carrier with double functions of overcoming and preventing P-glycoprotein-mediated tumor multidrug resistance. The gold medicinal nano-carrier is prepared by connecting a synergistic hydrophilic ligand for enhancing intake of nano-materials and a medicine-carrying ligand for carrying hydrophobic medicines to a gold nano-material by a ligand exchange method, wherein the synergistic hydrophilic ligand is a thiolated PEG 5000 (polyethylene glycol 5000) molecule with electropositive amino group at the terminal, and the medicine-loading ligand is a thiolation modified beta-cyclodextrin molecule; the gold medicinal nano-carrier is of a spherical shape. Experiments prove that a paclitaxel-loaded gold medicinal nano-carrier prepared by adsorbing the gold nano-carrier to paclitaxel can be used for effectively killing cells with P-glycoprotein drug resistance, can avoid drug resistance generation while killing cells without P-glycoprotein drug resistance, and provides a new thought and new direction to nano-medicine loading methods in overcoming tumor multidrug resistance.